“…However, neuroprotection is still a choice, and oxidative stress, a suitable biological target. In this context, antioxidants such as N - t -butylphenylnitrone (PBN; Figure 1; Novelli et al, 1986) and NXY-059 (Figure 1; Dehouck et al, 2002), have attracted the interest of a number of laboratories, resulting in therapeutic candidates for cancer (Inoue et al, 2007; Floyd et al, 2008, 2010, 2011; Costa et al, 2015), neurodegenerative disorders (Floyd et al, 2000), hearing loss (Floyd et al, 2008) and stroke (Doggrell, 2006; Floyd et al, 2008). NXY-059 (Figure 1) (Kuroda et al, 1999) is a well-known free radical scavenger with good neuroprotective profile in rat models of transient and permanent focal ischemia, and stroke model in rodents, which has been launched several times in different program in advanced clinical studies, although with limited success (Macleod et al, 2008).…”